Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma

Inclusion Criteria

• Histologically confirmed diagnosis of multiple myeloma (International Classification of Disease [ICD-10] code: C90.0)
• Previous exposure to at least one proteasome inhibitors (PI) and lenalidomide (or candidacy for isatuximab as per updated Food and Drug Administration [FDA] package insert information in the future)
• Planned or current isatuximab-containing therapy. Patients receiving isatuximab as part of a clinical trial are eligible for this study if allowed by the trial sponsor. * For ease of registration, patients will be allowed to enroll at any point after the decision is made to initiate isatuximab (with the understanding that their initial doses will be SOC, including the first 2 doses for all patients). However, RI isatuximab will only be administered to participants who have not had IRRs during >= 2 consecutive prior doses of SOC isatuximab
• Ability to understand a written informed consent form (ICF) document, and the willingness to sign the ICF document

Exclusion Criteria

• Age < 18
• Body weight > 70 kg at the time of any RI isatuximab dose
• Current pregnancy or (if of reproductive age) unwillingness to follow contraception requirements as per the FDA package insert
• New York Heart Association Stage IV heart disease, i.e. unable to carry on any physical activity without discomfort or symptoms of heart failure (as per study investigator)
• Any medical condition, including mental illness or substance abuse, deemed by the PI to interfere with the ability to provide consent or cooperate with study procedures